Last reviewed · How we verify
VLA15 with Alum
At a glance
| Generic name | VLA15 with Alum |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Injection site pain
- Myalgia
- Headache
- Fatigue
- Injection site erythema
- Injection site induration
- Injection site swelling
- Arthralgia
- Nausea
- Influenza like illness
- Upper respiratory tract infection
- Pyrexia
Key clinical trials
- Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis (PHASE2)
- Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis (PHASE1)
- Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VLA15 with Alum CI brief — competitive landscape report
- VLA15 with Alum updates RSS · CI watch RSS
- Pfizer portfolio CI